by Leishmaniasis refers to a group of parasitic diseases that are transmitted by the bite of infected female phlebotomine sand flies. It causes a range of clinical symptoms, the most common being cutaneous leishmaniasis (CL) that causes skin sores, and visceral leishmaniasis (VL) affecting internal organs. Currently there are no vaccines for leishmaniasis prevention and treatment mainly involves chemotherapy with drugs such as miltefosine, paromomycin, amphotericin B and antimony compounds. These drugs suffer from severe toxic side effects and emerging drug resistance.
The global leishmaniasis treatment market is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22.% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Global Leishmaniasis Treatment Market Size are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. These players are focusing on development of targeted drug therapies with improved safety profiles to address the growing resistance towards conventional drugs.
The key opportunities in the market include growing burden of leishmaniasis disease worldwide especially in tropical and subtropical regions, rising government funding for development of new treatment options and favorable regulatory environment for orphan drugs.
Advances in drug delivery strategies and development of immunotherapy and gene therapy approaches are contributing significantly towards the technological advancement in leishmaniasis treatment landscape. Drugs based on RNA interference, vaccines, monoclonal antibodies and host-directed therapies hold promise.
Market Drivers
Growing disease incidence due to increasing environmental changes facilitating sand fly vector proliferation is a major market driver. According to the WHO, there are an estimated 0.2 to 0.4 million new cases of VL and 0.7 to 1.2 million new cases of CL annually globally. Other key drivers include lack of immunization and limited infrastructure in endemic regions for disease control.
Current Challenges in Leishmaniasis Treatment Market
The leishmaniasis treatment market is facing numerous challenges currently. Some major challenges include lack of effective treatments for all forms of leishmaniasis, limited research efforts for developing next generation treatments, growing resistance to existing drugs, complicated diagnostic protocols, and limited financing for research and development activities. Most of the current treatments have issues related to toxicity, required lengthy treatment duration and parenteral administration. Moreover, treatment options for cutaneous leishmaniasis caused by species like L. guyanensis and L. panamensis remain limited. Diagnosis of leishmaniasis also poses challenges as conventional methods like microscopy and culture are insufficiently sensitive and specificity. Access to healthcare in endemic regions also acts as a barrier. Overcoming these challenges will be important for sustained growth of this market.
SWOT Analysis
Strengths: Presence of large number of treatment options compared to past. Drugs like miltefosine provide oral treatment option.
Weaknesses: Issues related to toxicity, resistance and required lengthy treatment of existing drugs. Limited diagnostic and screening methods.
Opportunities: Significant research on newer drug targets and diagnostic methods provide scope for next generation treatments. Rising cases in new geographic areas indicate potential for market expansion.
Threats: Threat from drug resistant strains pose risks. Limited funding for research may slow drug development efforts.
Leishmaniasis Treatment Market: Geographical Regions Analysis
In terms of value, North America currently accounts for the major share in the leishmaniasis treatment market led by the US. This is attributed to relatively high healthcare spending and availability of advanced treatment and diagnostic options in the region. South America is another prominent regional market driven by prevalence of leishmaniasis in countries like Brazil, Colombia and Venezuela. The Middle East and Africa region is also a major market owing to presence of significant leishmaniasis burden countries like Saudi Arabia, Syria and Sudan. Asia Pacific market is expected to witness fastest growth over the forecast period due rising cases in India and presence of other endemic countries in the region.
Leishmaniasis Treatment Market: Fastest Growing Geographical Region
The Asia Pacific region is projected to be the fastest growing market for leishmaniasis treatment during the forecast period from 2024 to 2030. This can be attributed to rising prevalence and incidence rates in major endemic countries like India. Growing awareness about diagnosis and treatment along with availability of affordable generic drugs are supporting factors for market growth. India accounts for over 50% of the total leishmaniasis patients globally, which translates to a sizable patient pool. Governments in various Asia Pacific countries have also implemented several initiatives and programs for controlling leishmaniasis, thereby promoting market growth. Increasing healthcare spending provides further opportunities for market participants in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
